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ABSTRACT
Aggressive meningiomas exhibit high levels of recurrence, morbidity and
mortality. When surgical and radiation options are exhausted, there is need for novel
molecularly-targeted therapies. We have recently identified NDRG4 overexpression in
aggressive meningiomas. NDRG4 is a member of the N-Myc Downstream Regulated
Gene (NDRG) family of the alpha/beta hydrolase superfamily. We have demonstrated
that NDRG4 downregulation results in decreased cell proliferation, migration and
invasion. In follow up to our prior studies; here we demonstrate that the predominant
form of cell death following NDRG4 silencing is apoptosis, utilizing Annexin-V flow
cytometry assay. We show that apoptosis caused by p53 upregulation, phosphorylation
at Ser15, BAX activation, Bcl-2 and BcL-xL downregulation, mitochondrial cytochrome c
release and execution of caspases following NDRG4 depletion. Sub-cellular distribution
of BAX and cytochrome c indicated mitochondrial-mediated apoptosis. In addition, we
carried out the fluorescence cytochemical analysis to confirm mitochondrial-mediated
apoptosis by changes in mitochondrial membrane potential (Ψm), using JC-1 dye.
Immunoprecipitation and immunofluorescence confirmed binding of NDRG4 to p53. In
addition, we demonstrate that apoptosis is mitochondrial and p53 dependent. The
proapoptotic effect of p53 was verified by the results in which a small molecule
compound PFT-α, an inhibitor of p53 phosphorylation, is greatly protected against
targeting NDRG4 induced apoptosis. These findings bring novel insight to the roles of
NDRG4 in meningioma progression. A better understanding of this pathway and its
role in meningioma carcinogenesis and cell biology is promising for the development
of novel therapeutic targets for the management of aggressive meningiomas.

a recurrence rate of greater than 40%, and WHO Grade III
tumors recur over 80% of the time with death occurring
within a decade after diagnosis [6, 7]. Malignant tumor
progression depends upon the capacity of tumor cells
to invade, metastasize and promote an angiogenic host
response. Though surgery and radiation are important
to therapy, there are few adjuvant therapies available
to patients which are unresectable or recur. However,
tumor growth rate following radiation therapy remains
an intimidating clinical challenge with few effective
alternative therapeutic options [8]. Alternative treatment
options are required for patients with either malignant
or recurrent benign meningiomas that are surgically
inaccessible. There is a need for novel molecular targets

INTRODUCTION
Meningiomas represent one third of all primary
central nervous system neoplasms [1]. They are the
second most common brain tumors, and originate from the
arachnoid “cap” cells of the arachnoid villi [2, 3]. While
most meningiomas are benign, up to 15% are aggressive
and characterized by a capacity for normal brain invasion
with frequent and destructive recurrence patterns.
Maximally safe surgical resection is the standard of care
for all subtypes and grades of meningioma with adjuvant
radiotherapy often used for aggressive tumor variants, or
recurrent WHO Grade I tumors [4, 5]. WHO Grade II has
www.impactjournals.com/oncotarget
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to improve survival and reduce morbidity for this group of
patients. We recently showed that N-Myc down regulated
gene 4 (NDRG4) was overexpressed in aggressive
meningioma [9]. NDRG4 is involved in modulating cell
proliferation, invasion, migration and angiogenesis in
meningioma, and may play a valuable role as a molecular
target in its treatment.
The N-Myc downstream-regulated gene (NDRG)
family consists of NDRG1–4, these are identified as
a novel class of Myc repressed intracellular proteins
consisting of 340–394 amino acid residues with 57–65%
sequence homology [10, 11]. The NDRG family proteins
are members of the alpha/beta hydrolase super family;
these α/β-hydrolases exhibit multiple surface hydrophobic
residues that facilitate their molecular interactions [12].
Although the functional role in cellular progression has
not yet been identified, NDRG4 have been identified as a
novel interaction partner for Bves (Blood vessel epicardial
substance). However, these protein-protein interactions
have been mostly characterized in epithelial cells that
influence epicardial cell movement [13]. NDRG proteins
have also been implicated in development [11, 14], cancer
metastasis [15, 16], and the immune system [17, 18].
Each of the four NDRG proteins demonstrates a distinct
spatiotemporal expression pattern during embryonic
development and in adult tissues [19, 20]. NDRG2 and
NDRG4 are highly expressed in brain and heart [21] and
promote neurite extension in PC12 neuronal cells [22, 23,
24]. Recent literature suggests that NDRG2 interacts with
p53 and regulates apoptosis in oxygen-glucose deprived
C6-originated astrocytes [25]. This p53 interaction
seems to be preserved in human lung, breast and brain
malignancies [26].
NDRG4 has roles in development; including
zebrafish myocyte proliferation [10] and normal brain
development and function [27]. However NDRG4 also
been identified as a tumor suppressor gene with NDRG4
overexpression resulting in decreased colorectal cancer
cell proliferation and invasion [28]. Most recently,
NDRG4 has been found to be upregulated in glioblastoma,
suggesting roles in cell cycle regulation and survival [29].
The relationship between NDRG4 and cell survival in
meningioma is not established yet in vivo but knockdown
of NDRG4 decreases migration, invasion and inhibited
cell cycle progression in meningioma cells [9].
Cell proliferation and apoptotic cell death are very
complex processes that involve the participation of a host
of genes. In both events, p53 is one of the most important
and studied tumor suppressor genes [30]. P53 maintains
tumor suppression by transcriptional regulation of genes
involved in cell growth and apoptosis [31]. Elevated
levels of p53 are observed in malignant meningiomas
and overexpression of p53 is associated with high
levels of cellular proliferation, rapid tumor recurrence
and radioresistance [32]. The p53 tumor suppressor
protein mediates a range of mitochondria mediated
www.impactjournals.com/oncotarget

apoptotic responses initiated by various external and
internal stimuli [33]. The fundamental consequences of
mitochondrial-mediated apoptosis include the unstablised
mitochondrial membrane integrity, cytochrome c
release and the activation of Bcl-2 family proteins [34].
BAX, a pro apoptotic protein is mainly localized in the
cytoplasm and translates into mitochondria in response
to apoptotic stimuli [35]. The extrinsic pathway of
apoptosis requires the cytochrome c release from the
mitochondrial intermembrane space to the cytosol [36].
Once released, cytochrome c cooperates with the adaptor
protein, APAF-1, to promote the activation of caspases,
which are required for the rapid recognition, triggers DNA
fragmentation and clearance of the abnormal cells [37].
Our research involves the discovery of targets
that would enhance the effects of meningioma cancer
treatment. RNA interference-based, targeted silencing
of gene expression is a strategy of potential interest for
cancer therapy [38]. Currently, attempts are being made to
overcome the adverse effects and limitations of radiationresistant tumor cells using the gene therapy [39]. However,
the detailed contribution of the NDRG4 protein and its
biological significance in malignant meningiomas has not
been studied. The mechanism of action of the depleted
NDRG4 induced cell death was unknown. In the present
study, to better characterize the key roles of NDRG4 in
vitro, we have used a lentiviral vectors expressing small
hairpin RNA directed against NDRG4. We demonstrate for
the first time that downregulation of NDRG4 gene activates
p53 by phoshorylation at Ser15, increased BAX expression
and translocation into mitochondria, which leads to
destabilization of mitochondria which has ultimately induces
the activated caspase mediated apoptosis in meningioma
tumor cells. It is clear that the understanding of NDRG4
function in the development of meningioma pathology may
give new insights in future therapeutic strategies including
gene therapy. Hence, selectively targeting NDRG4 with
lentiviral mediated gene silencing may be a potential cancer
therapy for malignant meningiomas.

RESULTS
Knockdown of NDRG4 regulates cell proliferation
and induces the apoptosis in meningioma
To evaluate the role of NDRG4 in cell proliferation
and cell death in meningioma cells, NDRG4 was targeted
in IOMM-Lee and CH-157 MN cells using specific
lentiviral shRNA vectors. IOMM-Lee and CHMN-157
are the most frequently used and well characterized
high-grade meningioma cell lines. Knockdown of
NDRG4 gene was confirmed using immunoblots after
viral purification. Targeting of NDRG4 significantly
decreased proliferation rates in both IOMM-Lee
(74.93%, p = 0.1072) at 24 hrs, 63.0%, p = 0.0048 at
17595
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48 hrs and 38.15%, p = 0.0002 at 72 hrs) and CH-157
MN (71.51%, p = 0.0108 at 24 hrs, 56.65%, p = 0.0001
at 48 hrs and 42.65%, p = 0.0002 at 72 hrs) compared
to control cells. In both the cell lines targeting NDRG4
significantly decreased proliferation (Figure 1A). We
further analyzed these cells for apoptosis using Annexin
V- APC assay. Knockdown of NDRG4 induced 43.2%
of early apoptosis and 18.4% of late apoptosis in the
IOMM-Lee cells and 4% early apoptosis and 29.4%
late apoptosis in the CH MN-157 cells was detected.
Targeting NDRG4 significantly induced apoptosis in
both IOMM-Lee (65%; p = 0.0001) and CH-157 MN
cells (31%; p = 0.0061) when compared to control cells
(Figure 1B). These results indicate that NDRG4 regulated
proliferation and prevented apoptosis in IOMM-Lee and
CH-157 MN cells.

and observed a two-fold increase of caspase 9 activity in
NDRG4 knockdowned cells than the control vector and
untransduced cells (Figure 2B). These results indicate
induction of intrinsic like apoptosis in the absence of
NDRG4 in meningioma cells.

Targeting the NDRG4 induces mitochondrialmediated apoptosis
To determine the role of NDRG4 in mitochondrialmediated apoptosis, we analyzed the mitochondrial
and cytosolic fractions in NDRG4 knockdowned and
control IOMM-Lee and CH-157 MN cells. We observed
increased BAX and decreased cytochrome c expression
in mitochondrial fractions of NDRG4 knockdowned
cells when compared to control cells (Figure 3A).
Correspondingly we observed that there was increased
BAX and decreased cytochrome c expression in
cytoplasmic fractions in control cells when compared
to NDRG4 kncockdowned cells. These results suggest
that BAX translocates to the mitochondria and releases
cytochrome c to the cytosol leading to induction of
intrinsic like apoptosis. Analyzing the lysates with COX
IV and GAPDH checked the purity of the fractions.
Since mitochondrial membrane potential (Ψm) damage
is a key event that causes the activation of caspases,
cytochrome c release into cytosol. We determined the
Ψm using cytofluorometric lipophilic cationic dye,
JC-1 by confocal microscopy. We observed more JC-1
aggregates (red fluorescence) in NDRG4 targeted cells
at 24 hrs, however at later time points (72 hrs), JC-1

NDRG4 regulates apoptotic signaling in
meningioma cells
To determine the role of NDRG4 in the molecular
mechanism of apoptosis, we analyzed mitochondrial
Bcl-2 family protein expression in presence or absence
of NDRG4 in meningioma cell lines by western
Immunoblotting, 72 hrs post infection. Targeting
NDRG4 in IOMM-Lee cells and CH-157 MN cells led
to increased accumulation of pro apoptotic protein BAX
and decrease in anti-apoptotic proteins Bcl-2 and BclxL. Targeting of NDRG4 also led to increased caspase 9,
caspase 3 and PARP 1 activity (Figure 2A). We further
validated the caspase 9 activity by calorimetric assay

Figure 1: Knockdown of NDRG4 decreases the cell viability and induces the apoptosis. A. IOMM-Lee and CH-157 MN cells were

infected with viruses generated in HEK 293T cells transfected with Control vector (CTR) or NDRG4 (shND) specific shRNA. Equal numbers of
IOMM-Lee and CH-157 MN cells were plated in 96-well plates after gene silencing. After 24 hrs, 48 hrs and 72 hrs, cells were treated with MTT and
the cell viability was determined using a colorimetric cell proliferation assay. Shown is the percent viability. Error bars indicate SEM (*p < 0.05,
n = 3). B. Suppression of NDRG4 gene expression induces apoptosis in IOMM-Lee and CH-157 MN cells. IOMM-Lee and CH-157 MN cells
were infected with lentivirus generated in HEK 293T cells transfected with Control vector or NDRG4 specific shRNA. 72 hrs of post transduction,
untreated (UT), control (CTR) and shNDRG4 (shND) treated cells were stained with Annexin V-APC/propidium iodide and analyzed by flow
cytometry. The graph indicating the percent apoptosis for each treatment group is shown SEM of triplicates. *p < 0.05.
www.impactjournals.com/oncotarget

17596

Oncotarget

Figure 2: Silencing NDRG4 induces apoptosis through the mitochondrial apoptotic pathway. A. IOMM-Lee and

CH-157 MN cells were infected with lentivirus generated in HEK 293T cells transfected with control vector or NDRG4 specific shRNA.
The knockdowned cells were lysed using RIPA/MPER buffer. 40 μg cell lysate of mitochondrial apoptotic proteins: BAX, BcL2,
BcL-xL, cleaved Caspase 9, cleaved Caspase 3 and PARP I were immunoblotted. B. Caspase 9 enzyme activity assay. IOMM lee and CH-157
MN cells were infected with viruses generated in HEK 293T cells transfected with control vector or NDRG4 specific shRNA. 72 hrs of post
transduction, untreated, control and shNDRG4 treated cells were lysed using RIPA/MPER and 40 μg of cell lysate were incubated with a
LEHD-pNA substrate. Caspase 9 activity was measured at 405 nm. The graph indicating the OD at 405 nm for each treatment group is shown
in triplicates. Error bars indicate SEM (*p < 0.05, n = 3).

Figure 3: A. Subcellular distribution of BAX and cytochrome c. IOMM lee and CH-157 MN cells were infected with lentivirus

generated in HEK293T cells transfected with control vector or NDRG4 specific shRNA. 72 hrs of post transduction, untreated, control and
shNDRG4 treated cytosolic (40 μg) and mitochondrial (40 μg) protein fractions were immunoblotted-using antibodies to cytochrome c and BAX.
GAPDH and COX IV were used to determine loading in cytosolic and mitochondrial fraction respectively. B. Mitochondrial membrane potential
damage (ΔΨm). Mitochondrial membrane potential damage was evaluated using JC-1 reagent. To determine the initiation of mitochondrial
apoptosis IOMM-Lee cells were infected with lentivirus generated in HEK 293T cells transfected with control vector or NDRG4 specific shRNA.
After 24 hrs, 48 hrs 72 hrs and 96 hrs of post transduction, untreated, control and shNDRG4 treated cells were collected and stained with JC-1
fluorescence dye and images were captured with confocal microscopy. We carried out Immunofluorescence analysis of mitochondrial membrane
potential by JC-1 staining for decreased red fluorescence (JC-1 aggregates) and increased green fluorescence (JC-1 monomers).
www.impactjournals.com/oncotarget
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aggregates were diminished and JC-1 monomers (green
fluorescence) increased in the cytosol (Figure 3B).
At 96 hrs, both the monomeric form and dimeric forms
were diminished due to apoptosis. NDRG4 targeted
cells showed loss of mitochondrial membrane potential
indicating mitochondrial depolarization. These results
suggest that NDRG4 plays a vital role in maintaining
mitochondrial membrane potential and preventing
apoptosis in meningioma cells.

Targeting NDRG4 led to activation of p53 (Ser15) and
stabilization of total p53 in both IOMM-Lee cells and
CH-157 MN cells when compared to control cells
(Figure 4A). Total p21 in NDRG4 targeted and control
cells remained unaltered. These results indicate that
p53 induces apoptosis in meningioma cells when
NDRG4 is knockdowned. Since p53 was activated in
NDRG4 targeted cells, we wanted to determine if there
was a direct interaction between p53 and NDRG4. We
performed an Immunoprecipitation assay to test for
NDRG4 and p53 molecular interactions. Protein lysates
of IOMM-Lee and CH-157 MN cells in the presence
and absence of NDRG4 were immunoprecipated with
NDRG4 antibody and probed for p53 and NDRG4 by
western blotting (Figure 4B). Western immunoblotting
revealed that NDRG4 indeed interacted directly with
p53 and that p53 was present only in the control and

NDRG4 directly regulates p53 activity
NDRG proteins directly or indirectly associate
with variety of other proteins and activate intracellular
signaling pathways [13, 25, 40]. We investigated the
protein levels of various pro-apoptotic proteins like
p53, p21 and phospho-p53 Ser15 by western blotting.

Figure 4: A. Knockdown of NDRG4 enhances p53 activity. IOMM-lee and CH-157MN cells were infected with viruses generated

in HEK 293T cells transfected with Control vector or NDRG4 specific shRNA. The knockdowned cells were lysed using RIPA/MPER and
40 μg of cell lysates were immunoblotted for total p53, phospho p53 (Ser 15) and p21 protein levels. GAPDH was used to determine protein
loading. B. NDRG4 directly interacts with p53. IOMM-lee and CH-157 MN cells were infected with lentivirus generated in HEK 293T
cells transfected with control vector or NDRG4 specific shRNA. 72 hrs of post transduction, untreated, control and shNDRG4 treated total
cellular protein fractions were Immunoprecipitated-using antibodies to-NDRG4 and probed with p53 antibody. C. P53 and NDRG4 colocalization. Immunocytochemical colocalization of NDRG4 and p53 in IOMM-Lee and CH 157-MN control cells. NDRG4 is conjugated
with Alexa Fluor 594 secondary antibody. P53 is conjugated with Alexa Fluor 488 secondary antibody. Co-localization of NDRG4 and p53
was detected in IOMM-Lee and CH 157 MN control cells. All experiments were performed in triplicate (n = 3). D. Subcellular localization
of NDRG4. IOMM lee and CH-157 MN cells were infected with lentivirus generated in HEK293T cells transfected with control vector or
NDRG4 specific shRNA. 72 hrs of post transduction, untreated, control and shNDRG4 treated nuclear fraction (NF) (40 μg) and cytosolic
fraction (CF) (40 μg) protein fractions were immunobltted-using antibodies to NDRG4. Lamin A/C and PCNA were used to determine
loading in nuclear fraction.
www.impactjournals.com/oncotarget
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untransduced lysates and absent in NDRG4 targeted
lysates. Further we performed immunocytochemical
staining of p53 and NDRG4 in IOMM-Lee and CH157
MN cells. Immunocytochemical analysis showed
expression of both p53 (green) and NDRG4 (red)
in IOMM-Lee and CH157 MN cells (Figure 4C).
The overlay images revealed co-localization of
p53 and NDRG4 (Figure 4C). In the fluorescence
Immunocolocalization analysis of p53 and NDRG4, we
observed the nuclear expression of NDRG4 in both the
cell lines. To confirm the nuclear localization of NDRG4
we analyzed the NDRG4 protein levels in the nuclear
and cytosolic extracts of NDRG4 knockdown and control
cells by Immunoblotting (Figure 4D). Analyzing the
lysates with Lamin A/C and PCNA checked the purity
of the nuclear fractions. We observed NDRG4 protein
expression in both the nuclear and cytosolic fractions of
control cells rather than the cells knockdown of NDRG4.
Comparatively with nuclear NDRG4, cytosolic NDRG4
protein expression was high in both IOMM-Lee and CH
157 MN cells. These results indicate that there is a direct
interaction between NDRG4 and p53 predominantly in
the cytosol.

between NDRG4 and p53, we wanted to determine if
p53 played a direct role in NDRG4-mediated apoptosis
in meningioma cells. We inhibited p53 using PFT-α and
analyzed apoptosis in meningioma cells in the presence and
absence of NDRG4. Targeting NDRG4 significantly induced
the apoptosis in both IOMM-Lee cells (43%; p = 0.0366) and
CH-157 MN (33%; p = 0.0275) when compared to controls
(Figure 5A). Inhibition of p53 by PFT-α (10 μM) abrogated
the shNDRG4 induced apoptosis in IOMM-Lee (11%; p = <
0.05) and CH-157 MN (11%; p < 0.05) cells (Figure 5A). To
evaluate the role of p53 in the absence of NDRG4 induced
apoptosis, cells were pre-treated with Pifithrin-α (PFT-α) in
the various conditions, and analyzed by Western blotting.
Western immunoblots showed activation of p53 when
NDRG4 was targeted in both IOMM-Lee and CH-157 MN
cells (Figure 5B), and this activation was abrogated when
p53 was inhibited with PFT-α (10 μM). Taken together these
results indicate that inhibition of p53 prevented mitochondrial
apoptosis in NDRG4 targeted meningioma cells.

DISCUSSION
The management of recurrent and high grade
meningiomas remains a challenge. The key is to elucidate
disease mechanisms, validate therapeutic targets, and
develop new therapeutic strategies. We believe that our
studies evaluating the role of NDRG4 in meningioma
biology are important for meeting that challenge.

Inhibition of p53 attenuates NDRG4 targeted
mitochondrial-mediated apoptosis
Since we observed induction and stabilization of p53
in the absence of NDRG4 and also detected direct interaction

Figure 5: Inhibition of p53 abrogates targeted NDRG4 induced apoptosis. IOMM-lee and CH-157 MN cells were infected
with lentivirus generated in HEK 293T cells transfected with control vector or NDRG4 specific shRNA. PFT-α (10 μM) was added to the
cells after 4 hrs of infection. 72 hrs of post transduction, untreated, control and shNDRG4 treated cells were stained with Annexin V-PE/
7-AAD and analyzed by flow cytometry. A. The graph indicating the percentage of apoptosis for each treatment group is shown SEM of
triplicates. *p < 0.05. B. 40 μg of the above shNDRG4 ± PFT-α treated cell lysate were immuno blotted with NDRG4 and Phospho p53
(Ser15). Beta actin was used to determine protein loading.
www.impactjournals.com/oncotarget
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NDRG4 plays varied roles in tumor suppression
and progression in various cancers [29] [28, 41]. In our
previous studies, we demonstrated that NDRG4 was
overexpressed in IOMM-Lee and CH-157 MN cells and
NDRG4 silencing inhibited cell proliferation, motility,
invasion and angiogenesis in high grade meningioma
cell lines [9]. In this study we demonstrate the molecular
mechanisms of cell death associated with NDRG4 gene
knockdown.
Proliferation and apoptotic cell death are complex
processes involving many genes. Given the increased
expression levels in aggressive meningiomas, studies were
best undertaken first with NDRG4 protein depletion. We
utilized lentiviral-mediated short hairpin RNA interference
(52 MOI) to knockdown expression of NDRG4. In this
manner, we demonstrated robust cellular death upon
NDRG4 gene knockdown within the IOMM-Lee and
CH-157 MN cell lines. NDRG4 gene knockdown
significantly induced apoptosis as determined by FACS
analysis (Figure 1B). This cell death was in the form of
apoptosis as seen in GBM [29], and we proceeded to
characterize the form of apoptosis.
Mitochondria represent the central checkpoint
in apoptotic signaling [42, 43, 44]. Following NDRG4
silencing, we observed loss of mitochondrial membrane
potential in NDRG4 targeted IOMM-Lee and CH-157
MN cell lines (Figure 3B), consistent with membrane
depolarization. We then characterized the signaling
associated with mitochondrial dependent apoptosis.
NDRG4 gene knockdown resulted in decreased
expression of Bcl-2 and BcL-xL, translocation of
activated BAX into the mitochondria, cytochrome c
release and enhanced cleaved caspase expression in
meningioma cells (Figure 3A).
P53 overexpression is reported in several human
malignant tumors [45] and elevated levels of wild type
p53 are observed in aggressive malignant meningiomas
[32]. P53 mediated BAX activation and induction of
caspases, and apoptosis execution has been identified
in multiple diseases including cancer [46, 47, 48].
Moreover, p53 has been linked to the mitochondrial
intrinsic like apoptotic pathway by novel transcriptionindependent interactions with antiapoptotic and
proapoptotic members of the Bcl-2 family proteins
[49, 50]. Activated p53 can induce the expression
of p21, which participates in cell cycle arrest, BAX
expression, mitochondrial membrane potential damage
and activation of caspases that lead to apoptosis [51].
In NDRG4 depleted meningioma we observed increased
p53 activity and stabilization which activated effector
caspases by releasing mitochondrial cytochrome c into
the cytoplasm. NDRG4 gene knockdown induced
apoptosis was associated with p53 phoshorylation at
Ser15 without a change in total p53 or p21 expression
levels (Figure 4A). Similar data showing apoptotic cell
death was reported in embolized meningiomas [52].
www.impactjournals.com/oncotarget

NDRG4 gene knockdown results in BAX translocation
in an indirect manner. According to the existing reports on
the p53 intrinsic apoptotic pathway, phosphorylated p53
induces the BAX stimulation [53, 54]. Bcl-2 inhibits BAX
dimerization and translocation into mitochondria. In our
studies we have identified Bcl-2 inhibition (Figure 2) in the
absence of NDRG4. These indirect downstream signaling
of apoptotic response is mediated by p53. However,
p53 is activated after the dissociation from NDRG4. We
demonstrate that p53 activation occurs in the absence of
NDRG4 (Figure 4A), that there is a direct interaction between
NDRG4 and p53. These results were clearly showed in the
protein-protein interaction studies (Figure 4B, 4C). However,
there is much data demonstrating mitochondrial dependent
apoptotic signaling downstream of p53 activation. In terms of
BAX translocation and its mechanism [53] and downstream
apoptosis signaling [54, 55].
NDRG4 gene knockdown results in intrinsic like
apoptosis and our data suggest that this is p53 dependent.
Similar reports of NDRG proteins roles in p53 mediated
apoptosis are present in various cancers [25, 26, 56].
We demonstrated that p53 and NDRG4 co-localize,
and immunoprecipitation experiments show p53 in the
lysates of controls cells but not in the NDRG4 depleted
lysates (Figure 4B, 4C). This suggests a possibly direct
role of NDRG4 in interaction with p53 and indirect role
in downstream signaling of apoptotic response. Further
we have demonstrated the subcellular levels of NDRG4
(Figure 4D) because of nuclear localization of NDRG4 was
observed in the fluorescence colocalization studies. These
resulted confirmed the nuclear and cytoplasmic localization
of NDRG4. Whereas p53 and NDRG4 interaction was much
observed in the cytoplasm (Figure 4C). We believe that
the cytoplasmic NDRG4 and p53 interaction was playing
a crucial role in the regulation of apoptosis. In addition,
we demonstrated that NDRG4 depleted meningioma cells
treated with Pifitrhin-α which inhibits p53 activity, observed
the significant inhibition of apoptotic cell death by Annexin
-V assays. Furthermore, protein expression analysis of
Phospho-p53 in PFT-α treated cells in the presence or
absence of NDRG4 confirmed the role of p53 activity in
triggering the apoptotic signal.
In summary, this is the first report demonstrating that
NDRG4 silencing induces apoptotic cell death in aggressive
meningioma cell lines. These findings advance our
understanding of the role of NDRG4 in tumor progression;
suggest a role for NDRG4 as a novel oncogenic protein, and
as a potential therapeutic target for a difficult disease.

MATERIALS AND METHODS
Cells lines and chemicals
Human meningioma cancer cell lines IOMM-Lee
and CH-157 MN were kindly provided by Dr. Yancie
Gillespie, University of Alabama in Birmingham and Dr.
17600
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Anita Lal – University of California, San Francisco and
grown in DMEM, DMEM/F12 media containing 10%
fetal bovine serum and 1% penicillin/streptomycin. All
cell lines were maintained in a 37°C incubator in a 5%
CO2-humidified atmosphere.
NDRG4 specific shRNA sequence (CAAACTAT
GCTTCAACACCTT) and control shGFP sequence (CGAC
GTAAACGGCCACAAGTT) cloned into a lentiviral
packaging vector (pLKO.1) were obtained from the Genome
Institute at the Washington University School of Medicine in
St Louis, USA. Lentiviral packaging (pCMVdR8.2dvpr) and
envelope (pCMV-VSV-G) vectors and were obtained from
Adgene, Cambridge, MA. Antibodies to NDRG4 (39) V:
sc-100788, p53 (D)-1): sc-126, p53 (3H2821): sc-56179),
p53 (FL-393) sc-6243, p21 (F5): sc-6246, BAX(N20):
sc-493, BAX(B-9): sc-7480, Bcl-xL (H-5): sc-8392, Bcl2 (N-19): sc-492, PARP-1 (H-250): sc-7150, β-Actin
(c4); sc-47778, GAPDH(A-3): sc-137179 and Pifitrhin-α
were obtained from Santa Cruz Biotechnology . Anti-p53
(ab2433) was purchased from Abcam. p53(1C12) Mouse
mAb #2524, Phospho-p53 (Ser15) (16G8) Mouse Ab #9286,
Caspase-9 (mouse specific) #9504, cleaved Caspase-3
(Asp175) #9661, COX IV antibody #4844 and Anti Rabbit
HRP-linked IgG #7074B were obtained from Cell Signaling.
Alexafluor 488 anti mouse-Ab, was from Invitrogen. HRP
Goat anti-mouse IgG antibody was from BioLegend.

added into each well to a final concentration of 5 mg/ml.
The insoluble Formosan was collected and dissolved in
dimethylsulfoxide (DMSO, 0.5%) and absorbance was
measured at 570 nm (Bio-Tek,).

Immunoblot analysis
The treated cells were washed with PBS, and lysed
using M-PER mammalian protein extraction reagent
with protease inhibitor cocktail. The lysates were
homogenized by sonication and protein concentration
was determined using the BCA protein assay reagent.
Cellular protein (40 μg) was separated using 10–14%
SDS- PAGE and transferred onto PVDF membranes.
Proteins were analyzed with specific primary antibodies
and developed using a horseradish peroxidase-conjugated
anti rabbit or anti-mouse IgG secondary antibody.
Specific proteins were detected with western lighting
Plus - ECL and using Bio-Rad Image lab images were
scanned.

Isolation of nuclear and cytosolic extracts
Nuclear and cytosolic extracts from the treated
cells were isolated using Chemicon International
nuclear extraction kit. Cells were washed once with
1X ice cold PBS, the cell pellet was resuspended in 1X
cytosolic lysis buffer and incubated on ice for 15 min
and homogenized the cells using 20–25 times with 27
gauge needle syringe. The lysates were centrifuged at
8000 g for 20 min at 4oC. The supernatant that included
the cytosolic portion of the cell lysate was collected. The
remaining pellet containing the nuclear portion of the
cell lysates were suspended in ice cold nuclear extraction
buffer and homogenized. The nuclear suspension was
centrifuged at 16000 g for 5 min at 4oC to collect the
nuclear fraction. Immunoblot analysis was performed
with the cytoplasmic and nuclear fractions for proteins
like NDRG4, Lamin A/C and PCNA.

Lentiviral transduction and knockdown of
NDRG 4 in meningioma cell lines
Recombinant lentiviral particles were produced
in HEK293-T cells by co-transfecting lentiviral (LV)
plasmid containing NDRG4 or control shRNA, along with
the packaging vector pCMVdR8.2dvpr, and a plasmid
encoding the vesicular stomatitis virus coat envelope
pCMV-VSV-G. Lentiviral purification and infection of
target cells were done as described earlier [57, 58]. Briefly
IOMM-Lee and CH-157 MN cells were infected with
medium containing virus (shNDRG4 or control shRNA)
along with Polybrene (8 μg/ml) to enhance infectivity
(16 hrs). A multiplicity of infection (MOI) of 52 was
used for our experiments. Cells were washed with PBS
and replenished with regular growth medium for 48–72
hrs. The transduced cells were selected by using 2 μg/ml
Puromycin [9].

Isolation of mitochondrial and cytosolic extracts
Mitochondrial and cytosolic extracts from
the treated cells were isolated using Active Motif
mitochondrial fractionation kit. Cells were washed once
with 1X ice cold PBS, the cell pellet was resuspended
in 500 μl of 1X cytosolic buffer incubated for 15
min at 4°C on a rocking platform and homogenized
the cells using 20–25 times with 0.5 ml syringe. The
lysates were centrifuged at 3000 rpm for 20 min at
4oC. The supernatant that included the cytosolic and
mitochondrial fraction was collected. The supernatant
was centrifuged at 10,000 rpm for 20 minutes at 4°C
to separate the mitochondria as a pellet and cytosolic
fraction as the supernatant. The Mitochondrial pellet
was washed with 100 μl 1X cytosolic buffer and
centrifuged at 10,000 rpm for 10 min at 4°C to collect

Cell proliferation assay
Cell proliferation was evaluated using the
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide dye method. Equal numbers (20, 000) of IOMMLee and CH MN 157 cells were seeded in a volume of
100 μL in each well of 96-well plate for 24 hrs. Cells
were infected with viruses generated in HEK293T cells
transfected with GFP or NDRG4 specific shRNA for
24 hrs, 48 hrs and 72 hrs. After incubation, MTT was
www.impactjournals.com/oncotarget
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Apoptosis assay

the mitochondrial pellet and dissolved in 100 μl of
complete mitochondrial buffer. Immunoblot analysis
was performed with the cytoplasmic and mitochondrial
fractions for proteins like BAX, COX IV, Cytochrome
C and GAPDH.

Apoptosis was determined using apoptosis
detection kit (BD Pharmingen, USA). Cells (100,000)
were incubated with Annexin V-APC/PE and propidium
iodide/7-AAD for 15 min at room temperature. The cells
were then analyzed by flow cytometry, using a two-color
FACS analysis system (BD LSR II). For each treatment,
the average fold-increase of apoptotic cells over control
was calculated.

Mitochondrial membrane potential damage
IOMM-Lee cells (2 × 105) were infected
with lentivirus containing shNDRG4 for 24 hrs,
48 hrs, 72 hrs and 96 hrs. Cells were then stained
with 2.5 μM JC-1 (5, 5, 6, 6-tetrachloro-1, 1, 3, 3tetraethylbenzimidazolylcarbocyanineiodide, Cayman
Chemicals) for 30 min at 37°C, and Digital pictures
for JC monomers (Green fluorescence; 535 nm) and JC
aggregates (red fluorescence; 570 nm ) were captured by
confocal microscope (Zeise LSM 510).

Statistical methods
Statistical analysis and graphical presentation was
done using quantitative data from MTT assay, FACS
analysis and other assays were evaluated for statistical
significance using GraphPad Prism 4.0. Data for each
treatment group were represented as means ± SEM and
compared with other groups for significance by oneway ANOVA. Results presented in this study are the
representative images of three independent experiments
(n = 3) and results are expressed as mean ± SEM. and
differences were considered significant at a p value of less
than 0.05.

Immunoprecipitation
Cell lysates (400 μg) from shGFP and shNDRG4
transduced cell lines were incubated with NDRG4 specific
antibody (2 μg) overnight at 4°C. Following incubation
30 μl of protein G coupled magnetic beads (MACS) were
added to antibody conjugated protein and incubated for
30 min on ice. The immunoprecipitated protein lysate
complex was then added to the pre-equilibrated micro
columns (miltenybiotec) and washed with lysis buffer
and eluted with 1X SDS sample buffer containing
β-Mercaptoethanol at 90°C. The Immunoprecipitated
protein was resolved on SDS-PAGE and immunoblotted
for p53 and NDRG4.
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